No­vavax's vac­cine roll­out crawls amid months of bro­ken promis­es — re­port

For No­vavax, part of the big ques­tion sur­round­ing the biotech was whether it could man­u­fac­ture a Covid-19 vac­cine — its first com­mer­cial prod­uct — prop­er­ly, in suf­fi­cient quan­ti­ty and de­liv­er it on time.

With months of de­lays due to fil­ings and man­u­fac­tur­ing con­cerns, the an­swer to that ques­tion might just be no. The newest de­vel­op­ment for the biotech marks the lat­est in missed dead­lines and bro­ken pledges for the com­pa­ny — and the CEO who has a mul­ti­tude on his record.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER